Each week the pharmacists at the Repatriation General Hospital in Adelaide, Australia put out the RGH E-bulletin.
Sometimes I even put them up on this blog. I aim to get a little more serious about this. Though there is an archive (by date) over at my good friends at AusPharm I am now going to archive all bulletins on my blog. They will be listed by topic.
This means some bulletins will be listed twice. For instance the recent article on ‘Glucosamine in osteoarthritis: Update of the evidence’ will be stored under ‘G’ and ‘O’.
G
Glucosamine in osteoarthritis: Update of the evidence Volume 34 (12):July 20, 2009
O
Glucosamine in osteoarthritis: Update of the evidence Volume 34 (12):July 20, 2009
Hopefully this will make it easier to find information on a topic.
The bad news for some of you. Over the next couple of weeks the majority of the posts will be RGH E-Bulletins as I catch up with storing past bulletins on my blog. I might as well make them all seen as easily as possible by search engines.
However I am now finding some time (late at night!) to write again and posts on remote health, pharmacy and health will start to reappear.
The page will eventually make it onto my links. At the moment it can be found here.
If you like this post and what else you see on the blog please subscribe by RSS feed (the orange button) or by email. Visit my subscription page.
Tagged as:
Drug Information,
RGH E-bulletin
Antithrombin III (ATIII) is a glycoprotein that circulates in human plasma, and can inactivate thrombin and other proteases of the clotting cascade. Deficiency in ATIII leads to an increased risk of thrombus formation, due to prolongation of the circulation of activated clotting factors. The condition may be either inherited or acquired.
Click on the picture to download the small pdf file
The RGH E-bulletin is a joint initiative of the Patient Services Section and the Drug and Therapeutics Information Service of the Pharmacy Department, Repatriation General Hospital, Daw Park, South Australia. The RGH Pharmacy E-Bulletin is distributed in electronic format on a weekly basis, and aims to present concise, factual information on issues of current interest in therapeutics, drug safety and cost-effective use of medications.
Editor: Assoc. Prof. Chris Alderman, University of South Australia – Director of Pharmacy, RGH © Pharmacy Department, Repatriation General Hospital, Daw Park, South Australia 5041
If you like this post and what else you see on the blog please subscribe by RSS feed (the orange button) or by email. Visit my subscription page.
Tagged as:
Antithrombin,
deficiency,
Drug Information,
RGH Ebulletin
There has been a lot of discussion lately about the interaction between clopidogrel and the proton pump inhibitors (eg omperazole).
Clopidogrel is an antiplatelet drug. Well it is not really a drug. It is a prodrug and needs to be converted to an active metabolite in the liver. If you can get something to reduce Cytochrome CYP2C19 then clopidogrel is not metabolised and so no antiplatelet action occurs.
Yes you got it. The proton pump inhibitors can inhibit CYP2C19.
This bulletin from the Repatriation General Hospital in Adelaide sums up the latest evidence. Click on the picture below to download the small pdf.
If you like this post and what else you see on the blog please subscribe by RSS feed (the orange button) or by email. Visit my subscription page.
Tagged as:
clopidogrel,
Drug Information,
proton pump inhibitor,
RGH E-bulletin
There are currently several effective agents available to treat osteoporosis and for the prevention of fractures. Calcium and vitamin D play an important role for fracture prevention and bisphosphonates are the most commonly used antiresorptive agents. Partial oestrogen agonists such as raloxifene have a more limited role in the treatment of osteoporosis. Teriparatide, a recombinant human parathyroid hormone is approved for the treatment of osteoporosis in Australia but is does not attract a Pharmaceutical Benefit Scheme subsidy and its cost is widely regarded as prohibitive.
Denosumab is a novel therapy under investigation for the treatment of osteoporosis in post menopausal women. Receptor activity of nuclear factor kB ligand (RANKL) (a protein expressed by osteoblastic stromal cells) binds to receptor activator of nuclear factor k B (RANK) and is the primary mediator of osteoclast differentiation, activation and survival. RANKL is responsible for osteoclast mediated bone resorption. Osteoprotegerin, a soluble decoy receptor that binds RANKL is the key endogenous regulator of the RANKL-RANK pathway. Denosumab is a fully human monoclonal antibody that binds to RANKL with high affinity and specificity and blocks the interaction of RANKL with RANK mimicking the endogenous effects of osteoprotegerin, leading to decreased osteoclast action and subsequently less bone resorption.
For the full article (pdf) click on the picture below.
This newsletter is a joint initiative of the Patient Services Section and the Drug and Therapeutics Information Service of the Pharmacy Department, Repatriation General
Hospital, Daw Park, South Australia. The RGH Pharmacy E-Bulletin is distributed in electronic format on a weekly basis, and aims to present concise, factual information on issues of current interest in therapeutics, drug safety and cost-effective use of medications.
If you like this post and what else you see on the blog please subscribe by RSS feed (the orange button) or by email. Visit my subscription page.
Tagged as:
antibody,
Denosumab,
Drug Information,
monoclonal antibodies,
RGH E-bulletin
